ORXOF Stock Chart & Stats
$1.42
-$0.33(-15.71%)
At close: 4:00 PM EDT
$1.42
-$0.33(-15.71%)
Day’s Range― - ―
52-Week Range$0.78 - $4.09
Previous CloseN/A
Volume5.88K
Average Volume (3M)100.00
Market Cap
$21.37M
Enterprise Value$576.03M
Total Cash (Recent Filing)$276.90M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Oct 22, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume300
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap26.96
Enterprise Value/Revenue4.41
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda-2.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$1.91M
Bulls Say, Bears Say
Bulls Say
Improved Balance-Sheet LeverageVery low reported debt improves Orexo’s financial flexibility compared with its more leveraged history. A stronger solvency position can help the company fund development, manage volatility, and pursue partnerships without the same level of balance-sheet pressure.
Long-Dated Intellectual PropertyLong IP protection gives Orexo’s pipeline assets substantial time to build commercial value if development and regulatory milestones are achieved. Extended exclusivity can support durable pricing power, partnership interest, and future revenue protection.
Pipeline And Funding ProgressAdvancing multiple programs diversifies Orexo beyond its current marketed products and creates additional opportunities for future growth. BARDA reimbursement reduces funding pressure for OX390, while Izipry’s planned filing marks a material regulatory progression.
Bears Say
Severe Profitability And Revenue WeaknessMaterial revenue contraction combined with negative gross profit shows that Orexo’s current business is not covering its cost base. Persistent operating losses reduce internal funding capacity and make successful pipeline commercialization increasingly important to restoring earnings.
Volatile Cash GenerationLarge quarterly cash outflows can erode the resources available for clinical development and commercial operations, especially while revenue remains low. Although management reports cash on hand, repeated burn would increase dependence on cost reductions, partners, or external financing.
Unresolved DOJ ExposureAn unresolved DOJ matter creates continuing uncertainty around future cash obligations, legal expenses, and management attention. Until the issue is settled, it can complicate capital planning, constrain financing options, and make the company’s longer-term financial profile harder to stabilize.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $0.78 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $21.37M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 7 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -$0.228 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.062.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.22.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.228 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -23.043%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all ORXOF earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors